Transporters are membrane‐bound proteins that control the access of endogenous and
xenobiotics (drugs) to various sites in the human body. They influence drug …

Publisher Summary This chapter discusses the identification of drug interaction sites in P-
glycoprotein that behaves as an energy-dependent efflux pump capable of transporting …

In vitro evaluation of P-glycoprotein (P-gp) inhibitory potential is now a regulatory issue
during drug development, in order to predict clinical inhibition of P-gp and subsequent drug …

Multidrug resistance P-glycoprotein (P-gp; also known as MDR1 and ABCB1) is expressed
in the luminal membrane of the small intestine and blood–brain barrier, and the apical …

The magnitude of P-glycoprotein [(P-gp)/multidrug resistance protein 1 (MDR1)]-mediated
drug-drug interaction (DDI) at the blood-brain barrier (BBB) in rats was estimated by in vitro …

The drug-transport function of the human P-glycoprotein (Pgp or ABCB1) is inhibited by a
number of structurally unrelated compounds, known as modulators or reversing agents …

P-glycoprotein, the most extensively studied ATP-binding cassette (ABC) transporter,
functions as a biological barrier by extruding toxins and xenobiotics out of cells. In vitro and …

The most preferred route of administration for low-molecular-weight conventional drugs is
oral administration. Among the important questions that must be asked in the course of drug …

Purpose. The clinical utility of anthracyclines like idarubicin (IDA) is limited by the
occurrence of multidrug resistance and cardiotoxicity. Previous studies have demonstrated …

Transport molecules can significantly affect the pharmacodynamics and pharmacokinetics of
drugs. An important transport molecule, the 170kDa P-glycoprotein (Pgp), is constitutively …